Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANNX Stock Summary
Top 10 Correlated ETFs
ANNX
In the News

Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.

Why Shares of Annexon Are Plummeting Thursday
Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. The Active ETF portfolio continues with YTD gains at +14.2%.

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.

Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain. The 28 patients were dosed for six months and followed for three more.

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.

Annexon Biosciences to Participate in Upcoming May Investor Conferences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:
ANNX Financial details
ANNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.6 | -2.83 | -3.7 | -3.39 | -2.53 | |
Operating cash flow per share | -1.5 | -2.16 | -3.13 | -2.77 | -2.13 | |
Free cash flow per share | -1.5 | -2.18 | -3.16 | -2.81 | -2.25 | |
Cash per share | 3.86 | 3.35 | 20.7 | 6.33 | 4.44 | |
Book value per share | 3.31 | 3.32 | 20.3 | 6.05 | 4.23 | |
Tangible book value per share | 3.31 | 3.32 | 20.3 | 6.05 | 4.23 | |
Share holders equity per share | 3.31 | 3.32 | 20.3 | 6.05 | 4.23 | |
Interest debt per share | 0 | 0.36 | 0 | 0.85 | 0.67 | |
Market cap | 203.39M | 232.98M | 424.57M | 440.25M | 282.66M | |
Enterprise value | 159.22M | 189.04M | 156M | 400M | 175.5M | |
P/E ratio | -11.11 | -6.27 | -6.77 | -3.39 | -2.04 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -11.83 | -8.22 | -8 | -4.15 | -2.43 | |
PFCF ratio | -11.82 | -8.14 | -7.93 | -4.09 | -2.3 | |
P/B Ratio | 5.37 | 5.35 | 1.23 | 1.9 | 1.22 | |
PTB ratio | 5.37 | 5.35 | 1.23 | 1.9 | 1.22 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.94 | -5.9 | -2.46 | -3.06 | -1.21 | |
EV to operating cash flow | -9.26 | -6.67 | -2.94 | -3.77 | -1.51 | |
EV to free cash flow | -9.25 | -6.6 | -2.91 | -3.71 | -1.43 | |
Earnings yield | -0.09 | -0.16 | -0.15 | -0.3 | -0.49 | |
Free cash flow yield | -0.08 | -0.12 | -0.13 | -0.24 | -0.43 | |
Debt to equity | 0.27 | 0.15 | 0.03 | 0.24 | 0.23 | |
Debt to assets | 0.21 | 0.13 | 0.03 | 0.19 | 0.19 | |
Net debt to EBITDA | 2.48 | 1.37 | 4.23 | 0.31 | 0.74 | |
Current ratio | 13.74 | 9.21 | 33.33 | 11.39 | 11.1 | |
Interest coverage | 0 | -6.98 | 0 | 61.05 | -39.87 | |
Income quality | 0.94 | 0.76 | 0.84 | 0.81 | 0.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.02 | 0.06 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.03 | -0.54 | -0.7 | -0.77 | -3.1 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.91 | 14.55 | 41.08 | 21.49 | 15.51 | |
ROIC | 0.46 | 0.81 | 0.34 | -1.03 | 60.11 | |
Return on tangible assets | -0.38 | -0.75 | -0.18 | -0.45 | -0.49 | |
Graham Net | 2.98 | 2.87 | 20.02 | 4.9 | 3.45 | |
Working capital | 42.38M | 40.48M | 343.39M | 225.95M | 225.74M | |
Tangible asset value | 37.88M | 43.53M | 344.28M | 231.91M | 231.19M | |
Net current asset value | 35.44M | 39.04M | 342.34M | 192.56M | 194.2M | |
Invested capital | 0 | 0 | 0 | 0.15 | 0.14 | |
Average receivables | 0 | 152K | 41K | 1.5K | 0 | |
Average payables | 0 | 1.82M | 3.05M | 7.44M | 9.28M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.48 | -0.85 | -0.18 | -0.56 | -0.6 | |
Capex per share | 0 | -0.02 | -0.03 | -0.04 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.92 | -0.96 | -0.5 | -0.44 | -0.48 | |
Operating cash flow per share | -0.79 | -0.73 | -0.45 | -0.38 | -0.45 | |
Free cash flow per share | -0.92 | -0.75 | -0.45 | -0.38 | -0.45 | |
Cash per share | 5.36 | 4.6 | 3.93 | 3.35 | 3.09 | |
Book value per share | 5.2 | 4.36 | 3.8 | 3.19 | 2.91 | |
Tangible book value per share | 5.2 | 4.36 | 3.8 | 3.19 | 2.91 | |
Share holders equity per share | 5.2 | 4.36 | 3.8 | 3.19 | 2.91 | |
Interest debt per share | 0.89 | 0.89 | 0.51 | 0.49 | 0.4 | |
Market cap | 105.28M | 145.46M | 424.27M | 374.15M | 284.34M | |
Enterprise value | 26.63M | 74.98M | 247.32M | 266.98M | 172.73M | |
P/E ratio | -0.75 | -0.99 | -3.12 | -2.92 | -2 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.48 | -5.16 | -13.81 | -13.79 | -8.62 | |
PFCF ratio | -2.97 | -5.01 | -13.74 | -13.64 | -8.58 | |
P/B Ratio | 0.52 | 0.87 | 1.63 | 1.62 | 1.32 | |
PTB ratio | 0.52 | 0.87 | 1.63 | 1.62 | 1.32 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.76 | -2.03 | -6.96 | -7.28 | -4.19 | |
EV to operating cash flow | -0.88 | -2.66 | -8.05 | -9.84 | -5.24 | |
EV to free cash flow | -0.75 | -2.58 | -8.01 | -9.74 | -5.21 | |
Earnings yield | -0.34 | -0.25 | -0.08 | -0.09 | -0.13 | |
Free cash flow yield | -0.34 | -0.2 | -0.07 | -0.07 | -0.12 | |
Debt to equity | 0.25 | 0.31 | 0.2 | 0.23 | 0.25 | |
Debt to assets | 0.2 | 0.24 | 0.17 | 0.19 | 0.2 | |
Net debt to EBITDA | 2.25 | 1.91 | 4.98 | 2.92 | 2.71 | |
Current ratio | 12.39 | 8.95 | 13.59 | 11.1 | 10.14 | |
Interest coverage | -668.42 | -137.53 | -35.54 | -15.87 | 13.3 | |
Income quality | 0.86 | 0.76 | 0.88 | 0.79 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.17 | 0.03 | 0.01 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -10.07 | -1.59 | -0.33 | -0.53 | -0.26 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.35 | 9.68 | 6.51 | 5.64 | 5.62 | |
ROIC | -2.28 | -31.6 | 0.3 | 14.5 | 1.27 | |
Return on tangible assets | -0.14 | -0.17 | -0.11 | -0.11 | -0.13 | |
Graham Net | 4.06 | 3.24 | 3.17 | 2.61 | 2.36 | |
Working capital | 194.2M | 161.12M | 254.56M | 225.74M | 209.6M | |
Tangible asset value | 200.61M | 168.04M | 260.6M | 231.19M | 214.86M | |
Net current asset value | 161.3M | 128.71M | 222.66M | 194.2M | 178.62M | |
Invested capital | 0.17 | 0.2 | 0.13 | 0.14 | 0.15 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 10.27M | 9.84M | 8.61M | 7.17M | 8.88M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | -0.22 | -0.13 | -0.14 | -0.17 | |
Capex per share | -0.14 | -0.02 | 0 | 0 | 0 |
ANNX Frequently Asked Questions
What is Annexon, Inc. stock symbol ?
Annexon, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol ANNX
What is Annexon, Inc. stock quote today ?
Annexon, Inc. stock price is $2.945 today.
Is Annexon, Inc. stock public?
Yes, Annexon, Inc. is a publicly traded company.